Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 31.4% during trading on Monday . The stock traded as low as GBX 6.70 and last traded at GBX 6.70. 27,337,178 shares were traded during mid-day trading, an increase of 242% from the average session volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Stock Performance
The stock has a market cap of £37.20 million, a PE ratio of -8.31 and a beta of 1.53. The stock’s 50-day moving average is GBX 10.72 and its two-hundred day moving average is GBX 5.88.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- 3 Monster Growth Stocks to Buy Now
- Why Gold Loves Trump as Much as Trump Loves Gold
- Technology Stocks Explained: Here’s What to Know About Tech
- Google’s Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
